1 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet2 unknown3 Department of Clinical Medicine, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Københavns Universitet
Still no effective HIV-1 prophylactic or therapeutic vaccines are available. However, as the proportion of HIV-1-infected individuals on antiretroviral treatment is increasing, knowledge about the residual immune response is important for the possible development of an HIV-1 vaccine.
Journal of Acquired Immune Deficiency Syndromes (1999), 2013, Vol 63, Issue 4, p. 418-427
Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Female; HIV Core Protein p24; HIV Infections; HIV Integrase; HIV-1; HLA Antigens; Humans; Male; RNA, Viral; Viral Load; nef Gene Products, Human Immunodeficiency Virus; Journal Article; Research Support, Non-U.S. Gov't